Tackling TNBC recurrence with gdT cell immunotherapies

Triple negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer diagnoses. This aggressive subtype demonstrates a distinct clinical behavior, being more likely than other breast cancers to spread to other organs, particularly the lungs, within 5 years of diagnosis. Limited targeted treatment options underscore the urgent need for novel therapeutic approaches for TNBC patients. Now, research led by Professor Seth Coffelt at the University of Glasgow (UK) is illuminating a potential new path through immunotherapy, by harnessing the power of immune cells that appear naturally equipped to combat this aggressive disease. The breakthrough: Nature's cancer killers The...